Evaxion Biotech Q2 2024 GAAP EPS $(0.12) Beats $(0.26) Estimate, Sales $154.000K Beat $52.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech reported its Q2 2024 financial results, with a GAAP EPS of $(0.12), beating the estimate of $(0.26). The company also reported sales of $154.000K, significantly surpassing the estimate of $52.000K.
August 14, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech reported better-than-expected Q2 2024 results, with a GAAP EPS of $(0.12) beating the $(0.26) estimate and sales of $154.000K surpassing the $52.000K estimate.
The significant beat on both EPS and sales estimates is likely to positively impact Evaxion Biotech's stock price in the short term. Investors often react favorably to companies that exceed earnings and revenue expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100